Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,"Irritation Assessments, Treatment-Emergent Adverse Events (Teae)",3 Days,Primary Endpoint
1,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
2,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
3,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
4,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Study Drug Related Teaes,3 Days,Primary Endpoint
5,NCT04984707,Androgenetic Alopecia,Auc From,Not Mentioned,Total Exposure(Aucinf),48 Hours,Secondary Endpoint
6,NCT04984707,Androgenetic Alopecia,Auc From Time,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
7,NCT04984707,Androgenetic Alopecia,Maximum Observed Concentration,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
8,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Half Life（T½）,48 Hours,Secondary Endpoint
9,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Apparent Total Systemic Clearance,48 Hours,Secondary Endpoint
10,NCT04984707,Androgenetic Alopecia,Distribution(Vd/F),Not Mentioned,Apparent Volume,48 Hours,Secondary Endpoint
11,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Elimination Rate Constant（Kel）,48 Hours,Secondary Endpoint
12,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At Baseline.,Primary Endpoint
13,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,Immediately After Intervention.,Primary Endpoint
14,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 4 Weeks After Intervention.,Primary Endpoint
15,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 12 Weeks After Intervention.,Primary Endpoint
16,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 24 Weeks After Intervention.,Primary Endpoint
17,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At Baseline.,Primary Endpoint
18,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,Immediately After Intervention.,Primary Endpoint
19,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 4 Weeks After Intervention.,Primary Endpoint
20,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 12 Weeks After Intervention.,Primary Endpoint
21,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 24 Weeks After Intervention.,Primary Endpoint
22,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At Baseline.,Primary Endpoint
23,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,Immediately After Intervention.,Primary Endpoint
24,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 4 Weeks After Intervention.,Primary Endpoint
25,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 12 Weeks After Intervention.,Primary Endpoint
26,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 24 Weeks After Intervention.,Primary Endpoint
27,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At Baseline.,Primary Endpoint
28,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,Immediately After Intervention.,Primary Endpoint
29,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 4 Weeks After Intervention.,Primary Endpoint
30,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 12 Weeks After Intervention.,Primary Endpoint
31,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 24 Weeks After Intervention.,Primary Endpoint
32,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At Baseline.,Primary Endpoint
33,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,Immediately After Intervention.,Primary Endpoint
34,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 4 Weeks After Intervention.,Primary Endpoint
35,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 12 Weeks After Intervention.,Primary Endpoint
36,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 24 Weeks After Intervention.,Primary Endpoint
37,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global,At Baseline.,Secondary Endpoint
38,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global,Immediately After Intervention.,Secondary Endpoint
39,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global,At 4 Weeks After Intervention.,Secondary Endpoint
40,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global,At 12 Weeks After Intervention.,Secondary Endpoint
41,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global,At 24 Weeks After Intervention.,Secondary Endpoint
42,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At Baseline.,Secondary Endpoint
43,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Immediately After Intervention.,Secondary Endpoint
44,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 4 Weeks After Intervention.,Secondary Endpoint
45,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 12 Weeks After Intervention.,Secondary Endpoint
46,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 24 Weeks After Intervention.,Secondary Endpoint
47,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At Baseline.,Secondary Endpoint
48,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Immediately After Intervention.,Secondary Endpoint
49,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 4 Weeks After Intervention.,Secondary Endpoint
50,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 12 Weeks After Intervention.,Secondary Endpoint
51,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 24 Weeks After Intervention.,Secondary Endpoint
52,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At Baseline.,Secondary Endpoint
53,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,Immediately After Intervention.,Secondary Endpoint
54,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 4 Weeks After Intervention.,Secondary Endpoint
55,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 12 Weeks After Intervention.,Secondary Endpoint
56,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 24 Weeks After Intervention.,Secondary Endpoint
57,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue,At Baseline.,Secondary Endpoint
58,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue,Immediately After Intervention.,Secondary Endpoint
59,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue,At 4 Weeks After Intervention.,Secondary Endpoint
60,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue,At 12 Weeks After Intervention.,Secondary Endpoint
61,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue,At 24 Weeks After Intervention.,Secondary Endpoint
62,NCT04984564,Educational Problems,Not Mentioned,"Feedback Of Individual, Simulator Based Learning, Training On Virtual","Feedback Of Individual, Simulator Based Learning, Training On Virtual",Survey Was Conducted From August To July 2020. Subjects Had Two Month Period To Respond.,Primary Endpoint
63,NCT04984564,Educational Problems,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
64,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",In-Segment Late Lumen Loss,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
65,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",Not Mentioned,Not Mentioned,Target Lesion Failure,6 Months,Secondary Endpoint
66,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Mmp8,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
67,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Il1,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
68,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Rank-L,Baseline - 1 Week,Primary Endpoint
69,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Opg,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
70,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Cal,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
71,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Ppd,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
72,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Fmps,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
73,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Fmbs,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
74,NCT04983719,"Atypical, Myoma",Not Mentioned,"Evaluation, Video","Evaluation, Video",Day 1,Primary Endpoint
75,NCT04983719,"Atypical, Myoma",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
76,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
77,NCT04983641,Orthopedic Disorder,At-Visit Promis Completion Rates,"Orthopaedic Patients, Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message, Messages Prior","Orthopaedic Patients, Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message, Messages Prior",1 Week,Primary Endpoint
78,NCT04983641,Orthopedic Disorder,Not Mentioned,"Orthopaedic Patients, Overall (Pre-Visit, Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message, Messages Prior","Orthopaedic Patients, Overall (Pre-Visit, Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message, Messages Prior",1 Week,Primary Endpoint
79,NCT04983641,Orthopedic Disorder,Promis Form,Not Mentioned,Not Mentioned,1 Week,Secondary Endpoint
80,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Post-Operative Pain,One Week. Line Of 10 Points,Primary Endpoint
81,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
82,NCT04983459,"Prostatic Neoplasms, Recurrence",Rate Per Patient,"Pet-Psma, Biochemical Recurrence, Detection, Detection","Pet-Psma, Biochemical Recurrence, Detection, Detection",12 Months,Primary Endpoint
83,NCT04983459,"Prostatic Neoplasms, Recurrence",Rate Per,"Biochemical Recurrence, Region Of Psma-, Detection, Detection","Biochemical Recurrence, Region Of Psma-, Detection, Detection",12 Months,Secondary Endpoint
84,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Pelvic Examination,6 Months,Primary Endpoint
85,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
86,NCT04983212,Peri-Implantitis,Peri-Implantitis,Not Mentioned,Not Mentioned,01/01/2015 - 01/01/2020,Primary Endpoint
87,NCT04983212,Peri-Implantitis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
88,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,"Microparticles Derived From Endothelial Cells, Circulating Endothelial Progenitor Cells Concentration","Data Collected After 4 Weeks, 8 Weeks And 12 Weeks.",Primary Endpoint
89,NCT04983160,Chronic Kidney Disease,Micro Inflammation,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
90,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Blood Pressure,"Each Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks) For 24 Hours",Secondary Endpoint
91,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks)",Secondary Endpoint
92,NCT04983160,Chronic Kidney Disease,Microalbuminuria / Proteinuria,Not Mentioned,Not Mentioned,"Daily, Using First Urine Of The Day As A Sample.",Secondary Endpoint
93,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Scale In Obesity,Up To 12 Weeks,Primary Endpoint
94,NCT04983147,Obesity,Health,"Scale In Obesity, Importance","Scale In Obesity, Importance",Up To 12 Weeks,Primary Endpoint
95,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Sensitivity,Primary Endpoint
96,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Severity,Primary Endpoint
97,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Benefit,Primary Endpoint
98,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Barrier,Primary Endpoint
99,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
100,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
101,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
102,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Scale In Obesity,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
103,NCT04983147,Obesity,Health,"Scale In Obesity, Importance","Scale In Obesity, Importance","Through Study Completion, An Average Of 1 Year",Secondary Endpoint
104,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Sensitivity,Secondary Endpoint
105,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Severity,Secondary Endpoint
106,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Benefit,Secondary Endpoint
107,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Obesity- Perceived Barrier,Secondary Endpoint
108,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
109,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
110,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
111,NCT04983056,Fournier Gangrene,Number Of Patients,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
112,NCT04983056,Fournier Gangrene,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
113,NCT04982978,Vaping Related Disorder,Not Mentioned,"Effect, Vaping Intention","Effect, Vaping Intention",6-Weeks,Primary Endpoint
114,NCT04982978,Vaping Related Disorder,Perceived Vulnerability,Effect,Not Mentioned,6-Weeks,Secondary Endpoint
115,NCT04982978,Vaping Related Disorder,Perceived Severity,"Intention, Effect","Intention, Effect",6-Weeks,Secondary Endpoint
116,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Geometric Mean Ratio,1 Month,Primary Endpoint
117,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,90% Confidence,Primary Endpoint
118,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
119,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
120,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Geometric Mean Ratio,3 Months,Primary Endpoint
121,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,90% Confidence,Primary Endpoint
122,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
123,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
124,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Lungen - 6 (Kl-6),3 Months,Primary Endpoint
125,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
126,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
127,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
128,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
129,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
130,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Pittsburg Sleep Quality Index (Puqi),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
131,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
132,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
133,NCT04982523,Post Traumatic Stress Disorder,Change Of Post-Traumatic Stress Symptoms,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Primary Endpoint
134,NCT04982523,Post Traumatic Stress Disorder,Change,Not Mentioned,Depression,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
135,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
136,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Reading Speed,Not Mentioned,Not Mentioned,Day 0,Primary Endpoint
137,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Reading Speed,Not Mentioned,Not Mentioned,Month 3,Primary Endpoint
138,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,"Visual Acuity, Etdrs Chart Day",Not Mentioned,Day 0,Secondary Endpoint
139,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,"Visual Acuity, Etdrs Chartm3",Not Mentioned,Month 3,Secondary Endpoint
140,NCT04982341,Hypoxemic Respiratory Failure,Number Of Patients,Not Mentioned,Intubation,"Through Study Completion, An Average Of 28 Days",Primary Endpoint
141,NCT04982341,Hypoxemic Respiratory Failure,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
142,NCT04982263,Covid19,Not Mentioned,"Correlation, Results Of Laboratory Test, Disease Severity","Correlation, Results Of Laboratory Test, Disease Severity",Baseline Results Of Coagulation Profile And Baseline Disease Severity Assessment,Primary Endpoint
143,NCT04982263,Covid19,Not Mentioned,"Measured Inflammatory Markers, Coagulation Profile","Measured Inflammatory Markers, Coagulation Profile",Baseline Measurement Of Inflammatory Markers,Secondary Endpoint
144,NCT04982159,Invasive Fusariosis,Clinical Evolution,Not Mentioned,Not Mentioned,6 Weeks After Diagnosis,Primary Endpoint
145,NCT04982159,Invasive Fusariosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
146,NCT04982055,Critical Illness,Not Mentioned,Not Mentioned,Anti-Xa Activity,Peak Anti-Xa Activity Obtained 4 Hours After Start Of Low Molecular Weight Heparin Administration,Primary Endpoint
147,NCT04982055,Critical Illness,Auc (,Not Mentioned,Not Mentioned,0-24H,Secondary Endpoint
148,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Primary Endpoint
149,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Secondary Endpoint
150,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Treatment Emergent Adverse Events,28 Days,Primary Endpoint
151,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
152,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
153,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Plasma Concentration,72 Hours,Secondary Endpoint
154,NCT04981483,Placenta Accreta,Uterus,Not Mentioned,Not Mentioned,Intraoperative,Primary Endpoint
155,NCT04981483,Placenta Accreta,Number Of Units,Not Mentioned,Not Mentioned,Till 48 Hours Postpartum,Secondary Endpoint
156,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Rate Of Cesarean Hysterectomy Needed,Intraoperative And 48 Hours Postpartum,Secondary Endpoint
157,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Puerperal Sepsis,Till 6 Weeks Postpartum,Secondary Endpoint
158,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Clinical Findings,During The Study,Primary Endpoint
159,NCT04981379,Covid19,Complete Resolution,Not Mentioned,Not Mentioned,Fifth Day After Examination,Secondary Endpoint
160,NCT04981379,Covid19,Complete Resolution,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
161,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
162,NCT04981379,Covid19,"Igm,","Determination, Igg Levels","Determination, Igg Levels",Tenth Day After Examination,Secondary Endpoint
163,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
164,NCT04981379,Covid19,"Igm,",Determination,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
165,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Pneumonia,During The Study,Secondary Endpoint
166,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Mechanical Ventilation,During The Study,Secondary Endpoint
167,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
168,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Rate Of Discontinuation Of Treatments Due,During The Study,Secondary Endpoint
169,NCT04981379,Covid19,Not Mentioned,"Study Drugs, Symptoms After","Study Drugs, Symptoms After",During The Study,Secondary Endpoint
170,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Covid-19 Severe Infection,From 27-February-2020 To 15-June-2020,Primary Endpoint
171,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Covid-19 Mortality,From 27-February-2020 To 15-June-2020,Primary Endpoint
172,NCT04981249,"Covid-19, Chronic Disease",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
173,NCT04981197,Heart Failure,Not Mentioned,"Modified Piper Fatigue Scale Scores, Changes","Modified Piper Fatigue Scale Scores, Changes","Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
174,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
175,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
176,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
177,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,"Heart Rate Variability, Changes In","Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
178,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 58.2; Control 54.1),Primary Endpoint
179,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 89.3; Control 88.1),Primary Endpoint
180,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 36.9; Control 42.9),Secondary Endpoint
181,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 29; Control 70.5),Secondary Endpoint
182,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Detrusor Underactivity,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
183,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Bladder Outlet Obstruction,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
184,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
185,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Bladder Oversensitivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
186,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
187,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
188,NCT04981015,Bladder Oversensitivity,Between Parameters,Correlation,Not Mentioned,July 2009 To December 2020,Primary Endpoint
189,NCT04981015,Bladder Oversensitivity,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
190,NCT04980989,"Breast Cancer, Early-Onset",Modality,Not Mentioned,Not Mentioned,At 12 Months During Follow-Up Of Early Breast Cancer,Primary Endpoint
191,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Quality Of Life During Follow-Up Modality,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
192,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Patient Satisfaction,At 6 Months And 12 Months,Secondary Endpoint
193,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
194,NCT04980989,"Breast Cancer, Early-Onset",Other Healthcare,Not Mentioned,Not Mentioned,At 6 Months And 12 Months,Secondary Endpoint
195,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Successful Nerve Reconstruction,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
196,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
197,NCT04980729,Pelvic Tumor,Not Mentioned,"Template-Guided Group, Traditional Operation Group, Rotation Center Before","Template-Guided Group, Traditional Operation Group, Rotation Center Before","""Through Study Completion, An Average Of 2 Years""",Primary Endpoint
198,NCT04980729,Pelvic Tumor,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
199,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Primary Endpoint
200,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Specific Orofacial Muscles,Not Mentioned,Thickness Evaluation,Immediately After The Evaluation,Secondary Endpoint
201,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Cheeks Pressure,Immediately After The Evaluation,Secondary Endpoint
202,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Not Mentioned,Not Mentioned,Corpus Cavernosum Electromyography Amplitudes,1 Hour,Primary Endpoint
203,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Not Mentioned,Not Mentioned,Corpus Cavernosum Electromyography Relaxation Degree,1 Hour,Primary Endpoint
204,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
205,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Not Mentioned,48 Hours,Primary Endpoint
206,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Not Mentioned,28 Day Mortality,Secondary Endpoint
207,NCT04980274,Critically Ill Patients,Not Mentioned,Mechanical Ventilation,Not Mentioned,28 Days,Secondary Endpoint
208,NCT04980209,Femoroacetabular Impingement,Vas Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
209,NCT04980209,Femoroacetabular Impingement,Mhhs Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
210,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
211,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
212,NCT04980209,Femoroacetabular Impingement,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
213,NCT04980196,Urogenital Prolapse,Urological Outcome,Not Mentioned,Pelvic Organ Prolapse,3Months,Primary Endpoint
214,NCT04980196,Urogenital Prolapse,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
215,NCT04980131,Vertebral Fracture,Insertions Before,"Desired Position, Radiation Dosage Before Reaching, Rate,Number, Desired Position,","Desired Position, Radiation Dosage Before Reaching, Rate,Number, Desired Position,",Twenty Months,Primary Endpoint
216,NCT04980131,Vertebral Fracture,Vas Scores After,Not Mentioned,Not Mentioned,Twenty-Two Months,Primary Endpoint
217,NCT04980131,Vertebral Fracture,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
218,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Women Newly Diagnosed,"Breast Cancer 9 Weight Control, To Evaluate A Nutritional Intervention","Breast Cancer 9 Weight Control, To Evaluate A Nutritional Intervention",Six Months,Primary Endpoint
219,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
220,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Adverse Events (Saes),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
221,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Unexpected Adverse Events,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
222,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Unexpected Adverse Drug Reactions (Adrs),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
223,NCT04980040,Type 2 Diabetes Mellitus,Haemoglobin (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
224,NCT04980040,Type 2 Diabetes Mellitus,Fasting Blood Glucose Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
225,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Overall Improvement,Up To Week 26,Secondary Endpoint
226,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Adverse Events (Saes),First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
227,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,"Adverse Drug Reactions (Adrs) Not Mentioned In Precautions, Unexpected Adverse Events (Aes)",First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
228,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Expected/Already Known Adrs,Week 13,Primary Endpoint
229,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Expected/Already Known Adrs,Week 26,Primary Endpoint
230,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Expected/Already Known Adrs,Week 39,Primary Endpoint
231,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Expected/Already Known Adrs,Week 52,Primary Endpoint
232,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Expected/Already Known Adrs,Week 153,Primary Endpoint
233,NCT04980014,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Abnormal Laboratory Findings Reported As Aes,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
234,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
235,NCT04980014,Type 2 Diabetes Mellitus,Change,"Fasting Serum Glucose, Baseline","Fasting Serum Glucose, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
236,NCT04980014,Type 2 Diabetes Mellitus,Change,"Baseline, Total Cholesterol","Baseline, Total Cholesterol","Baseline, Weeks 13 And 26",Secondary Endpoint
237,NCT04980014,Type 2 Diabetes Mellitus,Low Density Lipoprotein-Cholesterol (Ldl-C),Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
238,NCT04980014,Type 2 Diabetes Mellitus,High Density Lipoprotein-Cholesterol (Hdl-C),Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
239,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
240,NCT04980014,Type 2 Diabetes Mellitus,Change,"Blood Pressure, Baseline","Blood Pressure, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
241,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Diastolic,Secondary Endpoint
242,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,Operative Difficulties,At The Time Of Cholecysctomy,Primary Endpoint
243,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Postoperative Complications,Not Mentioned,Not Mentioned,30 Days After The Operation,Primary Endpoint
244,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
245,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,12Th Weeks,Primary Endpoint
246,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,"12Th Weeks, 5Th Day",Secondary Endpoint
247,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
248,NCT04979481,Mental Health Wellness 1,Resilience,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
249,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
250,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Self-Esteem,Up To 8 Months,Primary Endpoint
251,NCT04979481,Mental Health Wellness 1,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
252,NCT04979364,"Chronic Pain, Opioid Misuse",Pomi Scale,Not Mentioned,Not Mentioned,Once. At Inclusion (Test Phase),Primary Endpoint
253,NCT04979364,"Chronic Pain, Opioid Misuse",Pomi Scale,Not Mentioned,Not Mentioned,Once. At 2 To 4 Weeks (Re-Test Phase),Primary Endpoint
254,NCT04979364,"Chronic Pain, Opioid Misuse",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
255,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Delay For Ami Patient,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
256,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Delay For Stroke Patient,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
257,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
258,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Patient Survival,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
259,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
260,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
261,NCT04979091,"Covid19, Critical Illness",Sex,Not Mentioned,Covid-19 Patients,Day At Admission,Primary Endpoint
262,NCT04979091,"Covid19, Critical Illness",Sex,Critical Ill,Not Mentioned,Day At Admission,Primary Endpoint
263,NCT04979091,"Covid19, Critical Illness",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
264,NCT04979026,Deep Venous Thrombosis,Change Of,Not Mentioned,Not Mentioned,"The Peak Flow Velocity Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
265,NCT04979026,Deep Venous Thrombosis,Change,Not Mentioned,Not Mentioned,"The Flow Volume Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
266,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Stasis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
267,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Deep Venous Thrombosis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
268,NCT04979026,Deep Venous Thrombosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
269,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Primary Endpoint
270,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,7 Days,Secondary Endpoint
271,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
272,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Biomarkers Of Exposure, Nicotine Equivalents, Urine","Biomarkers Of Exposure, Nicotine Equivalents, Urine",14 Days,Secondary Endpoint
273,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Tsnas,"Urine:, Biomarkers Of Exposure","Urine:, Biomarkers Of Exposure",14 Days,Secondary Endpoint
274,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Carboxyhemoglobin,"Biomarkers Of Exposure, Blood:","Biomarkers Of Exposure, Blood:",14 Days,Secondary Endpoint
275,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Cotinine,"Biomarkers Of Exposure, Nicotine And, Blood:","Biomarkers Of Exposure, Nicotine And, Blood:",14 Days,Secondary Endpoint
276,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Feno,Biomarkers Of Potential,Not Mentioned,14 Days,Secondary Endpoint
277,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Biomarkers Of Potential,Not Mentioned,14 Days,Secondary Endpoint
278,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
279,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,B-Lymphocytes And,14 Days,Secondary Endpoint
280,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Platelet, Changes","Platelet, Changes",14 Days,Secondary Endpoint
281,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
282,NCT04978974,"Chronic Conditions, Multiple",Life,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
283,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Not Mentioned,Strategies Questionnaire,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
284,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,Booster (12 Weeks From Baseline),Primary Endpoint
285,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,6-Month Follow-Up,Primary Endpoint
286,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,"Study (Attrition, Satisfaction Ratings)",6-Month Follow-Up,Primary Endpoint
287,NCT04978961,Chronic Pain,Not Mentioned,Fact Intervention,Not Mentioned,6-Month Follow-Up,Primary Endpoint
288,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
289,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
290,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
291,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
292,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,Risk Factors,6 Months From Baseline,Primary Endpoint
293,NCT04978883,Sjogren'S Syndrome,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
294,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1. Week,Primary Endpoint
295,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4. Week,Primary Endpoint
296,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8. Week,Primary Endpoint
297,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
298,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
299,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
300,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
301,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
302,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
303,NCT04978805,Cancer,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
304,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
305,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
306,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
307,NCT04978688,Healthy,Area Under,Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
308,NCT04978688,Healthy,Maximum Concentration,Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
309,NCT04978688,Healthy,Change,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
310,NCT04978688,Healthy,Change,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
311,NCT04978688,Healthy,Change,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
312,NCT04978688,Healthy,Change,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
313,NCT04978688,Healthy,In N-Telopeptide,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
314,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events,8 Weeks,Secondary Endpoint
315,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Sanger,Not Mentioned,Not Mentioned,Change From Baseline To Postoperative 7 Days,Primary Endpoint
316,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Not Mentioned,"Total Bacteria, S3)","Total Bacteria, S3)",Change From Baseline To Postoperative 7 Days,Primary Endpoint
317,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
318,NCT04978532,"Procedural Pain, Pain, Acute",Change Of Pain From Before,Not Mentioned,Children),Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
319,NCT04978532,"Procedural Pain, Pain, Acute",Change Of Pain From Before,Observer),Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
320,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
321,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
322,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Not Mentioned,"Correlation, Glycemic Levels In Patients, Baseline, Changing Emotions","Correlation, Glycemic Levels In Patients, Baseline, Changing Emotions","Through Study Completion, An Average Of 1 Year",Primary Endpoint
323,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
324,NCT04978402,"Interchromosomal Breakpoint, Infertility",Not Mentioned,Not Mentioned,"Estimate The, Reproductive Risk, It Carrier",Day 1,Primary Endpoint
325,NCT04978402,"Interchromosomal Breakpoint, Infertility",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
326,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
327,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
328,NCT04978233,Covid-19,Not Mentioned,Healthcare Team,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
329,NCT04978233,Covid-19,Change In Symptoms,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
330,NCT04978233,Covid-19,Not Mentioned,Not Mentioned,Patient Satisfaction,From Day 1 To Day 14,Secondary Endpoint
331,NCT04978233,Covid-19,Change In,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
332,NCT04978233,Covid-19,Change In,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
333,NCT04978233,Covid-19,Change In,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
334,NCT04978233,Covid-19,Change In,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
335,NCT04978233,Covid-19,Change In,Not Mentioned,Blood Pressure,From Day 1 To Day 14,Secondary Endpoint
336,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
337,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Secondary Endpoint
338,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Not Mentioned,"Time Of, Postoperative",6 Weeks,Primary Endpoint
339,NCT04978155,Arterio-Venous Fistula,Planning Change,Not Mentioned,"Rate Of, Consultation, Surgical Project",During The Surgery,Secondary Endpoint
340,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Secondary Permeability,Not Mentioned,12 Months,Secondary Endpoint
341,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Improve Student,13 Lab Session-13 Weeks,Primary Endpoint
342,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Evaluate Effectiveness,Week 14,Primary Endpoint
343,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Assess Students' Perception Of Usability,Up To 15 Weeks,Secondary Endpoint
344,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Reduce Labor Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
345,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Postpartum Comfort Levels,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
346,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",A Maternal Information,Not Mentioned,Not Mentioned,Before Birth,Primary Endpoint
347,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Vasp),Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
348,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
349,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Evalution Labour Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
350,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Evalution Postpartum Comfort,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
351,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
352,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Patients Required,Not Mentioned,Renal Replacement Therapy,14 Days,Primary Endpoint
353,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
354,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Nash,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
355,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Not Mentioned,Not Mentioned,Normalization Of Hepatic Aminotransferases(Alt,3 Months,Secondary Endpoint
356,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Size,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
357,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Location,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
358,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,"Number, Lesions","Number, Lesions",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
359,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Margin,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
360,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Texture,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
361,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Pancreatic Tail Contraction,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
362,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Complicated Pancreatitis,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
363,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Pancreatic Duct/Bile Duct Dilatation,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
364,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Extrapancreatic Tissue Invasion,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
365,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
366,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
367,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Plain Scan,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
368,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Ct Value, Lesion Plain Scan",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
369,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Artery Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
370,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Ct Value, Lesion Artery Phase",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
371,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Portal Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
372,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,"Lesion Portal Phase, Ct Value",Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
373,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
374,NCT04977557,Dry Beriberi,Onls) Score,Not Mentioned,Overall Neuropathy,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Primary Endpoint
375,NCT04977557,Dry Beriberi,Change,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
376,NCT04977557,Dry Beriberi,Change In,Muscle Power,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
377,NCT04977557,Dry Beriberi,Change In,Not Mentioned,Muscle Cramp,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
378,NCT04977557,Dry Beriberi,Change In Deep Tendon Reflexes,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
379,NCT04977557,Dry Beriberi,Change,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
380,NCT04977557,Dry Beriberi,Change In Pain Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
381,NCT04977557,Dry Beriberi,Change,Not Mentioned,Position Sensation,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
382,NCT04977557,Dry Beriberi,Change,Not Mentioned,Vibration Sensation,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
383,NCT04977557,Dry Beriberi,Change,Not Mentioned,Touch Sensation,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
384,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,"Complications (Neurological Events, Congestive Heart Failure)","During The Hospitalization, Average Of 1 Months",Primary Endpoint
385,NCT04977518,Infective Endocarditis,Mortality,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
386,NCT04977518,Infective Endocarditis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
387,NCT04977505,Shoulder Dislocation,Not Mentioned,Hounsfield Unit,Not Mentioned,2 Years After Surgery,Primary Endpoint
388,NCT04977505,Shoulder Dislocation,The Diameter,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
389,NCT04977505,Shoulder Dislocation,Hounsfield Unit,Not Mentioned,Ossification Site,2 Years After Surgery,Primary Endpoint
390,NCT04977505,Shoulder Dislocation,Not Mentioned,Not Mentioned,Unossified Area,2 Years After Surgery,Secondary Endpoint
391,NCT04977505,Shoulder Dislocation,Ossification Quality Score,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
392,NCT04977440,Intensive Care Unit Syndrome,Glycemic Control,Effect,Not Mentioned,Up To 7 Days,Primary Endpoint
393,NCT04977440,Intensive Care Unit Syndrome,High Protein Intake,"Effect, Serum Electrolytes","Effect, Serum Electrolytes",Up To 7 Days,Primary Endpoint
394,NCT04977440,Intensive Care Unit Syndrome,Icu Outcome,Effect,Not Mentioned,Up To 7 Days,Secondary Endpoint
395,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Primary Endpoint
396,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
397,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
398,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Discharge Destination,Up To 55 Days,Secondary Endpoint
399,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Anxiety Visual,3Day,Primary Endpoint
400,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
401,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Richards-Campbell Sleep Scale,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
402,NCT04976673,"Lichen Planus, Oral",Not Mentioned,"Oral Lichen Planus, Size","Oral Lichen Planus, Size",12 Weeks,Primary Endpoint
403,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Rating,12 Weeks,Secondary Endpoint
404,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Not Mentioned,Not Mentioned,Rebleeding,6-Week,Primary Endpoint
405,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Not Mentioned,Not Mentioned,Death,6-Week,Secondary Endpoint
406,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Not Mentioned,Additional Warning Time,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Primary Endpoint
407,NCT04976504,"Desaturation Of Blood, Anesthesia",Between Ori,Correlation,Not Mentioned,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Secondary Endpoint
408,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Clinical Characteristics,Description,Not Mentioned,January 2017 - June 2021,Primary Endpoint
409,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,"Description, Tumor Nature","Description, Tumor Nature",January 2017 - June 2021,Primary Endpoint
410,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,"Description, Survival","Description, Survival",January 2017 - June 2021,Primary Endpoint
411,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
412,NCT04976361,Prp,Not Mentioned,Not Mentioned,Vessel Density,6 Months,Primary Endpoint
413,NCT04976361,Prp,Not Mentioned,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
414,NCT04976361,Prp,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
415,NCT04976114,Anxiety,Not Mentioned,Not Mentioned,Anxiety Level,"Presurgery, Just The Moment Before To Surgery",Primary Endpoint
416,NCT04976114,Anxiety,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
417,NCT04976088,"Trauma Injury, Inflammation",""" While","Treatment Start, Right Extreme Means ""Worst, Baseline, Left Extreme Means ""No Pain","Treatment Start, Right Extreme Means ""Worst, Baseline, Left Extreme Means ""No Pain",72 Hours,Primary Endpoint
418,NCT04976088,"Trauma Injury, Inflammation",Area Under,Curve (Auc),Not Mentioned,Day 4 And Day 8,Secondary Endpoint
419,NCT04976088,"Trauma Injury, Inflammation","Where ""No Pain",Baseline,Not Mentioned,"100"")",Secondary Endpoint
420,NCT04976088,"Trauma Injury, Inflammation","Where ""No Pain",Baseline,Not Mentioned,From Day 1 Until The Date Of Resolution Of Pain At Rest (Maximum Day 8),Secondary Endpoint
421,NCT04976088,"Trauma Injury, Inflammation","Where ""No Pain","Baseline, Treatment Start","Baseline, Treatment Start",Day 4 And Day 8,Secondary Endpoint
422,NCT04976088,"Trauma Injury, Inflammation",Movement),Not Mentioned,"Responder Patients (Defined, Treatment Start",Day 4,Secondary Endpoint
423,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,From Baseline To Day 8,Secondary Endpoint
424,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Baseline, Rescue Medication Consumed","Baseline, Rescue Medication Consumed",From Baseline To Day 8,Secondary Endpoint
425,NCT04976088,"Trauma Injury, Inflammation",Plaster Detached,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
426,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
427,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
428,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
429,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
430,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
431,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Baseline, Adverse Events","Baseline, Adverse Events","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
432,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Local Tolerability (Erythema), Investigator At Day, =Strong Reaction Spreading Beyond Test Site, =No Evidence","Day 1, Day 4 And Day 8",Secondary Endpoint
433,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"=Absent, Investigator At Day, =Severe, Local Tolerability (Itching)","Day 1, Day 4 And Day 8",Secondary Endpoint
434,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Local Tolerability (Burning), Investigator At Day, =Severe, =Absent","Day 1, Day 4 And Day 8",Secondary Endpoint
435,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"=Absent, Local Tolerability (Local Pain), Investigator At Day, =Severe","Day 1, Day 4 And Day 8",Secondary Endpoint
436,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"=Poor, =Excellent;, Global Assessment, =Good;, =Fair;, Investigator And Patient, Following Score","=Poor, =Excellent;, Global Assessment, =Good;, =Fair;, Investigator And Patient, Following Score",Day 4 And Day 8,Secondary Endpoint
437,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change In Pain Score,Mean,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
438,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change,"Mean, Inflammation",Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
439,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Chamber Inflammation,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
440,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Eyes Requiring Additional Post-Operative Therapy,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
441,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Patient Call-Backs,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
442,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Pharmacy,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
443,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Adverse Events,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
444,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change In Iop,Mean,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
445,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change In Bcva,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
446,NCT04975659,Communication,Pain Score,Not Mentioned,Not Mentioned,"Throughout Study Completion, Average Of 10 Months",Primary Endpoint
447,NCT04975659,Communication,Not Mentioned,"Baseline, Anxiety Score","Baseline, Anxiety Score","Through Study Completion, Average Of 10 Months",Primary Endpoint
448,NCT04975659,Communication,Education Level,Not Mentioned,Anxiety Score,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
449,NCT04975659,Communication,Association Of Past History,Not Mentioned,Anxiety Score,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
450,NCT04975542,Respiratory Function Impaired,Change In Chest Wall Excursion,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Chest Wall Excursion Within 5 Minutes Of Treatment Completion.,Primary Endpoint
451,NCT04975542,Respiratory Function Impaired,Change In,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fvc Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
452,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Not Mentioned,1 Second (Fev1,Primary Endpoint
453,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Fev1,Measure Assessing A Change From Baseline Fev1/Fvc Ratio Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
454,NCT04975542,Respiratory Function Impaired,Change In,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Respiratory Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
455,NCT04975542,Respiratory Function Impaired,Change In Heart Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Heart Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
456,NCT04975542,Respiratory Function Impaired,Not Mentioned,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Oxygen Saturation Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
457,NCT04975529,"Exercise, Diet",Change,"Mean, Baseline, Self-Reported Physical Activity","Mean, Baseline, Self-Reported Physical Activity",6-Months,Primary Endpoint
458,NCT04975529,"Exercise, Diet",Change,"Mean, Validated Physical, Baseline, Self-Reported Self-Efficacy For Physical Activity","Mean, Validated Physical, Baseline, Self-Reported Self-Efficacy For Physical Activity",6-Months,Secondary Endpoint
459,NCT04975529,"Exercise, Diet",Change,"Mean, Baseline, Self-Reported Dietary Intake","Mean, Baseline, Self-Reported Dietary Intake",6-Months,Secondary Endpoint
460,NCT04975529,"Exercise, Diet",Change,"Self-Confidence, Mean, Baseline, Positive Youth Development (Pyd) Short","Self-Confidence, Mean, Baseline, Positive Youth Development (Pyd) Short",6-Months,Secondary Endpoint
461,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Acne Severity,Initial Consult,Primary Endpoint
462,NCT04975412,Acne Vulgaris,Whole Blood,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
463,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Demographics,Initial Consult,Secondary Endpoint
464,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,At 07:00 Hours After Caffeine And Placebo Administration,Primary Endpoint
465,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Nocturnal Sleep,Between 03:00-07:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
466,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Caffeine Effects,Not Mentioned,Not Mentioned,Between 07:15-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
467,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:00-08:15 Hours After Caffeine And Placebo Administration,Secondary Endpoint
468,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:15-07:30 Hours After Caffeine And Placebo Administration,Secondary Endpoint
469,NCT04975360,"Sleep Inertia, Caffeine, Placebo",N-Back Task,Not Mentioned,Not Mentioned,Between 07:30-07:40 Hours After Caffeine And Placebo Administration,Secondary Endpoint
470,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Cortisol Awakening Response,Between 07:00-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
471,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Opportunity,Not Mentioned,Recording Of,Between 08:00-09:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
472,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Fitting,24 Months,Primary Endpoint
473,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
474,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Proximal Contact,24 Months,Primary Endpoint
475,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Marginal Adaptation,24 Months,Primary Endpoint
476,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Staining/Color Change,24 Months,Primary Endpoint
477,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Gingival Status,24 Months,Primary Endpoint
478,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Crown,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
479,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Veneer/Composite,Not Mentioned,24 Months,Primary Endpoint
480,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Secondary Caries,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
481,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Trauma,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
482,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Clinical Pulp Pathology,24 Months,Primary Endpoint
483,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Radiographical Pulp Pathology,24 Months,Primary Endpoint
484,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Esthetic Satisfaction,24 Months,Primary Endpoint
485,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
486,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Transition To Breastfeeding, Up To 1 Week.",Primary Endpoint
487,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Admission To Discharge, Up To 4 Weeks",Primary Endpoint
488,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
489,NCT04975126,Cataract,Decisional Conflict,Not Mentioned,Scale Score,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
490,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Decision Regret Scale Score,1 Month After Surgery,Primary Endpoint
491,NCT04975126,Cataract,Number Of Correctly,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
492,NCT04975126,Cataract,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
493,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Weeks,Not Mentioned,Not Mentioned,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
494,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Weeks,Not Mentioned,Quadriceps Femoris Muscles,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
495,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
496,NCT04975048,"Healthy, Gen1 Gene Mutation",Not Mentioned,Not Mentioned,"Serum Lipids, Changes","Week 0, Week 4, Week 8, Week 16",Primary Endpoint
497,NCT04975048,"Healthy, Gen1 Gene Mutation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
498,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
499,NCT04975022,"Pk, Pd, And Safety",Auc 0,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
500,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
501,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Tmax,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 Minutes；",Secondary Endpoint
502,NCT04975022,"Pk, Pd, And Safety",Auc 0,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120 Minutes",Secondary Endpoint
503,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Elimination Half-Life (T1/2),"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
504,NCT04975022,"Pk, Pd, And Safety",The Auc,Not Mentioned,Not Mentioned,4 H,Secondary Endpoint
505,NCT04975022,"Pk, Pd, And Safety",The Auc,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
506,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-2 Hours",Secondary Endpoint
507,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-4 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-4 Hours",Secondary Endpoint
508,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Tgirmax,"Pre-Dose, 0-8 Hours",Secondary Endpoint
509,NCT04974983,"Glioblastoma, Angiogenesis",Functional Outcome,Not Mentioned,Not Mentioned,15 Months,Primary Endpoint
510,NCT04974983,"Glioblastoma, Angiogenesis",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
